Skip to main content

Detection of Diffuse Myocardial Fibrosis in Patients with Nonischemic Cardiomyopathy: Cardiac MR Evaluation

Thursday, October 11, 2012 — Poster Session III

10:00 a.m. – Noon

Natcher Conference Center, Building 45




  • S. Liu
  • M. S. Nacif
  • C. T. Sibley
  • E. Yang
  • J. Han
  • D. A. Bluemke


Purpose: To evaluate CMR for quantifying diffuse interstitial fibrosis in heart failure (HF). Methods and Materials: Patients were enrolled in two groups: systolic HF (HFS) and diastolic HF (HFD). A healthy control group age matched was also enrolled. All CMR were performed on a 3T scanner with a bolus of 0.15mmol/kg of gadopentetate dimeglumine. A MOLLI T1 mapping sequence was acquired at short axis. Results: 28 subjects (19 patients, age 63±12 years and 9 matched healthy subjects, age 61±7 years) were evaluated. 15 had HFS and 4 had HFD. The ejection fraction (EF) was 62.0±5.8% in healthy, 63.5±11.3% in HFD and 31.0±7.3% in HFS. Pre-contrast T1 was lower in HF compared to healthy subjects (1196±29ms in HFD, 1255±15ms in HFS, and 1321±20ms in healthy, respectively, p=0.002 healthy vs. HFD, p=0.03 healthy vs. HFS). λ was greater in HFD and HFS compared to healthy subjects (48.5±1.5% in HFD, 50.9±0.9% in HFS, 45.8±1.2% in healthy, respectively, p=0.006 for healthy vs. HFS). ECV was also greater in HFD and HFS compared to healthy subjects (29.0±0.9% in HFD, 29.8±0.6% in HFS, 27.1± 0.7% in healthy, respectively, p=0.002 for healthy vs. HFS). Conclusion: ECV and λ are increased in HF subjects compared to healthy subjects.

back to top